CD33 and acute myeloid leukemia: The antibody against CD33, gemtuzumab (MylotargTM), has been tested for the treatment of AML, and was reported to be effective at inducing remissions in about 25-30% of relapsed AML patients despite its reversible toxicity on normal myeloid cells [34].